Motixafortide

About Gamida Cell

Gamida Cell pioneers nicotinamide-enhanced allogeneic cell therapies for hematologic conditions, with two FDA-approved products for transplantation and stem cell mobilization.

About BioLineRx

BioLineRx is a publicly traded, Israeli biotech company with a mission to develop best-in-class therapies for oncology and rare diseases. Its core strategy involves in-licensing and advancing novel drug candidates through clinical proof-of-concept, exemplified by the successful FDA approval and out-licensing of its stem cell mobilizer, motixafortide (APHEXDA®). The company has now pivoted back to a lean development model, focusing its resources on a promising new joint venture for GLIX1 in glioblastoma and a partnered Phase 2b trial in pancreatic cancer.

About BioLineRx

BioLineRx is a publicly traded, Israeli biotech company with a mission to develop best-in-class therapies for oncology and rare diseases. Its core strategy involves in-licensing and advancing novel drug candidates through clinical proof-of-concept, exemplified by the successful FDA approval and out-licensing of its stem cell mobilizer, motixafortide (APHEXDA®). The company has now pivoted back to a lean development model, focusing its resources on a promising new joint venture for GLIX1 in glioblastoma and a partnered Phase 2b trial in pancreatic cancer.

About BioLineRx

BioLineRx is a publicly traded, Israeli biotech company with a mission to develop best-in-class therapies for oncology and rare diseases. Its core strategy involves in-licensing and advancing novel drug candidates through clinical proof-of-concept, exemplified by the successful FDA approval and out-licensing of its stem cell mobilizer, motixafortide (APHEXDA®). The company has now pivoted back to a lean development model, focusing its resources on a promising new joint venture for GLIX1 in glioblastoma and a partnered Phase 2b trial in pancreatic cancer.

Therapeutic Areas